Eli Lilly and Co (NYSE:LLY) Price Target and Strategic Moves

Core Insights - Eli Lilly and Co (NYSE:LLY) is recognized for its innovative treatments and competitive strategies, with a price target set at $1,286 by Tim Anderson from National Bank, indicating a potential increase of 21.56% from the current price of $1,057.89 [1][6] Price Adjustments and Market Strategy - Eli Lilly has reduced the cash prices of its weight-loss drug, Zepbound, to enhance accessibility and affordability, with the 2.5 mg dose now priced at $299 (down from $349) and the 5 mg dose at $399 (down from $499) [2][4][6] - The price cuts for Zepbound follow agreements with US President Donald Trump aimed at improving access to GLP-1 drugs, aligning with the company's strategy to compete in the growing obesity treatment market [4] Stock Performance - Despite the price reductions, LLY shares have decreased by 0.8% to $1,066.96, although the stock has seen a 34% year-over-year increase, indicating strong long-term performance [3][6] - The stock has fluctuated between $1,055 and $1,084.15 on the current day, with a market capitalization of approximately $950.29 billion [5]